Artificial intelligence (AI)-driven drug discovery company Insilico Medicine has announced a first-of-its-kind documentary hackathon called Docuthon to encourage creative scientific exploration.
Credit: Insilico Medicine
Artificial intelligence (AI)-driven drug discovery company Insilico Medicine has announced a first-of-its-kind documentary hackathon called Docuthon to encourage creative scientific exploration.
The Company has collected substantial footage along its journey developing an end-to-end AI platform and expanding its global operations, including in-depth interviews with executives, scientists, and advisors like Nobel Prize winner in chemistry Michael Levitt. The footage provides candid looks into Insilico’s inner workings – solving scientific challenges, securing funding, and advancing a lead AI-discovered and AI-designed therapeutic for idiopathic pulmonary fibrosis into clinical trials.
Through Docuthon, participants from around the world are invited to utilize this footage to tell the story of Insilico Medicine and of advances in AI-powered drug discovery, an industry now at a tipping point. Films can be submitted as a documentary short or a documentary feature and cash prizes will be awarded for Best Feature, Best Short, Best Curated, and Most Creative.
Submissions will be judged based on their success at telling the story of AI drug development and of Insilico Medicine, on their scientific accuracy, and on the level of creativity and ability to hold the viewer’s interest.
Awards and prizes are as follows (prize amounts in USD):
- Best Feature: best long-form entry (16-60 min), $6K award
- Best Short: best short-form entry (3-15 min), $4K award
- Best Curated: best edited storyline among all entries, $5K award
- Most Creative: most creative format or plot among all entries, $5K award
- If the winners submitted more than one video with at least one long-form video, he/she shall be awarded another $2K on top of the amount given above.
“I have known since the Company’s early days that we were involved in something truly transformational, which is why I made sure to capture much of our journey on video,” says Insilico Medicine Founder and CEO Alex Zhavoronkov, PhD. “Now, our lead AI-discovered and AI-designed drug is in Phase 1 trials – the first such drug to reach this milestone – and we have 30 others in our internal pipeline. The time has come to bring this story to the broader world. In the process, I hope to inspire students and filmmakers who are excited about science, technology, and innovation and invite them to be a part of this story.”
Docuthon was officially launched by Zhavoronkov as a “one more thing” moment during Insilico Medicine’s Virtual Launch Event for its Pharma.AI platform – a global experience that brought thousands of viewers to witness the Company’s latest software updates, with special guests like Jensen Huang, founder, CEO and president of Nvidia, and Michael Antonov, founder of Formic Ventures and cofounder and chief software architect at Oculus.
Registration for Docuthon is open through March 1, 2023. Submissions are due in April 2023, and winners will be announced in May 2023. Additional details can be found at: https://insilico.com/docuthon.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
Website: www.insilico.com
Contact: media@insilico.com